Novavax announces that the first doses of the Nuvaxovid COVID-19 vaccine have started shipping to member states of the European Union.
Novavax, a biotechnology company dedicated to the development and commercialization of next-generation vaccines for serious infectious diseases, announced on February 23, 2022 that the first doses of its Nuvaxovid COVID-19 vaccine have begun shipping to member states of the European Union (EU). Nuvaxovid is the first protein-based COVID-19 vaccine authorized for use in Europe.
Nuvaxovid doses are shipped from Novavax’s Dutch distribution center to EU member states. The first wave of shipments includes several countries, such as Germany, France and Austria, and shipments to other EU member states will soon follow.
The European Commission (EC) has granted conditional marketing authorization (CMA) for Nuvaxovid to prevent COVID-19 caused by SARS-Cov-2 in people aged 18 years or older. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the authorization of the vaccine in all 27 EU member states in December 2021.
“Today’s announcement paves the way for the start of vaccination with Nuvaxovid in Europe in the coming days. The Novavax COVID-19 vaccine offers a differentiated option to boost vaccination rates across Europe,” said Stanley C. Erck, President and CEO of Novavax, in the press release. “Nuvaxovid has demonstrated efficacy, a reassuring safety and tolerability profile, and is built on a well-understood protein-based vaccine platform that has been used for other vaccines for decades.”